Protagenic Therapeutics, Inc.\new Available-for-sale Securities, Gross Realized Gain (Loss)
Protagenic Therapeutics, Inc.\new (PTIX) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $4.43 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2021-03-25
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-09-30 was $0.00.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-03-31 was $4.43K, a 465.69% increase year-over-year.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for fiscal 2019 was $4.43K, a 9.59% increase from fiscal 2018.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for fiscal 2018 was $4.05K, a 428.33% increase from fiscal 2017.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $766.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $4.43K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $4.43K 10-Q · filed 2020-11-16 | $6.91K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $4.43K 10-Q · filed 2020-08-14 | $6.91K derived: sum of 3 quarters · filed 2020-08-14 | $6.91K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $4.43K 10-Q · filed 2020-06-18 | $6.91K derived: sum of 2 quarters · filed 2020-06-18 | $6.91K derived: sum of 3 quarters · filed 2020-06-18 | $8.48K derived: sum of 4 quarters · filed 2020-06-18 |
| 2018-12-31 | $2.48K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-29 | $2.48K derived: sum of 2 quarters · filed 2020-04-29 | $4.05K derived: sum of 3 quarters · filed 2020-04-29 | $4.05K 10-K · filed 2020-04-29 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.57K derived: sum of 2 quarters · filed 2019-11-14 | $1.57K 10-Q · filed 2019-11-14 | $2.15K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $1.57K 10-Q · filed 2019-08-14 | $1.57K 10-Q · filed 2019-08-14 | $2.15K derived: sum of 3 quarters · filed 2019-08-14 | $3.21K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $784.00 10-Q · filed 2019-05-16 | $587.00 derived: sum of 2 quarters · filed 2019-05-16 | $1.64K derived: sum of 3 quarters · filed 2019-05-16 | $1.55K derived: sum of 4 quarters · filed 2019-05-16 |
| 2017-12-31 | -$197.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $858.00 derived: sum of 2 quarters · filed 2019-03-29 | $766.00 derived: sum of 3 quarters · filed 2019-03-29 | $766.00 10-K · filed 2019-03-29 |
| 2017-09-30 | $1.05K 10-Q · filed 2018-11-08 | $963.00 derived: sum of 2 quarters · filed 2018-11-08 | $963.00 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$92.00 10-Q · filed 2018-08-14 | -$92.00 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |